EBGI Category: Liver
-
Hepatocellular Carcinoma Incidence Rates Are 2%-3% in US Patients with Cirrhosis Regardless of Etiology
American College of Gastroenterology / EBGI Articles / Liver / Hepatocellular Carcinoma Incidence Rates Are 2%-3% in US Patients with Cirrhosis Regardless of EtiologyDrs Ashwini Arvind and Nicole E. Rich look at the decade-long, NIH-funded HEDS study for incidence and risk factors for hepatocellular carcinoma in cirrhosis.
-
Hepatitis C Virus Testing and Treatment – A Call To Action
American College of Gastroenterology / EBGI Articles / Liver / Hepatitis C Virus Testing and Treatment – A Call To ActionHepatitis C Virus Testing and Treatment: A Call to Action Sonali Paul, MD, MS Assistant Professor of Medicine, Division of …
-
ICYMI: Albumin Infusions Do Not Improve Outcomes in Hospitalized Patients with Decompensated Cirrhosis-The ATTIRE Trial
American College of Gastroenterology / EBGI Articles / Liver / ICYMI: Albumin Infusions Do Not Improve Outcomes in Hospitalized Patients with Decompensated Cirrhosis-The ATTIRE TrialIn Case You Missed It Albumin Infusions Do Not Improve Outcomes in Hospitalized Patients with Decompensated Cirrhosis: The ATTIRE Trial…
-
Bariatric Surgery Is Superior to Lifestyle Changes + Best Medical Care for Metabolic Dysfunction-Associated Steatohepatitis: The BRAVES Study
American College of Gastroenterology / EBGI Articles / Liver / Bariatric Surgery Is Superior to Lifestyle Changes + Best Medical Care for Metabolic Dysfunction-Associated Steatohepatitis: The BRAVES StudyBariatric Surgery Is Superior to Lifestyle Changes + Best Medical Care for Metabolic Dysfunction-Associated Steatohepatitis: The BRAVES Study Yichin Fu,…
-
Cephalosporins and Ciprofloxacin Still Appropriate First-Line Treatment for Spontaneous Bacterial Peritonitis
American College of Gastroenterology / EBGI Articles / Liver / Cephalosporins and Ciprofloxacin Still Appropriate First-Line Treatment for Spontaneous Bacterial PeritonitisEvidence-based summary of “Response-Guided Therapy with Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis: A Validation Study of 2021 AASLD Practice Guideline for SBP,” published in the American Journal of Gastroenterology.
-
Prophylactic Antibiotics Do Not Improve Mortality in Severe Alcoholic Hepatitis Treated with Corticosteroids
American College of Gastroenterology / EBGI Articles / Liver / Prophylactic Antibiotics Do Not Improve Mortality in Severe Alcoholic Hepatitis Treated with CorticosteroidsProphylactic Antibiotics Do Not Improve Mortality in Severe Alcoholic Hepatitis Treated with Corticosteroids Philip Schoenfeld, MD, MSEd, MSc (Epi) Chief…
-
ICYMI: Can we prevent hepatic decompensation? Most likely, with nonselective beta blockers
American College of Gastroenterology / EBGI Articles / Liver / ICYMI: Can we prevent hepatic decompensation? Most likely, with nonselective beta blockersIn Case You Missed It Can We Prevent Hepatic Decompensation? Most Likely, With Nonselective Beta Blockers Sonali Paul, MD, MS…
-
Direct-Acting Antiviral Therapy for Hepatitis C Virus Decreases All-Cause Mortality and Decompensated Cirrhosis: Treat (Virtually) Everyone
American College of Gastroenterology / EBGI Articles / Liver / Direct-Acting Antiviral Therapy for Hepatitis C Virus Decreases All-Cause Mortality and Decompensated Cirrhosis: Treat (Virtually) EveryoneDirect-Acting Antiviral Therapy for Hepatitis C Virus Decreases All-Cause Mortality and Decompensated Cirrhosis: Treat (Virtually) Everyone Philip Schoenfeld, MD, MSEd,…
-
ICYMI: Is Terlipressin for the Treatment of Hepato-Renal Syndrome Ready for Primetime: Results of the CONFIRM Trial
American College of Gastroenterology / EBGI Articles / Liver / ICYMI: Is Terlipressin for the Treatment of Hepato-Renal Syndrome Ready for Primetime: Results of the CONFIRM TrialThis summary reviews Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. N Engl J Med. 2021 Mar 4;384(9):818-828.
-
Prophylactic Rifaximin Decreases Post-TIPS Hepatic Encephalopathy
American College of Gastroenterology / EBGI Articles / Liver / Prophylactic Rifaximin Decreases Post-TIPS Hepatic EncephalopathyProphylactic Rifaximin Decreases Post-TIPS Hepatic Encephalopathy Philip Schoenfeld, MD, MSEd, MScEpi, FACG Chief Emeritus-Gastroenterology Section, John D. Dingell VA Medical…